Related Experiment Video
Updated: Feb 19, 2026
10:17
An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
Published on: November 3, 2010
23.4K
A functional ancestry-linked regulatory haplotype influences CYP2D6 expression
1Drug Metabolism and Pharmacokinetics & Modeling, Takeda Development Center Americas, Incorporation, Cambridge, MA, USA. Michael.McCoy1@Takeda.com.
The Pharmacogenomics Journal
|February 17, 2026
Summary
Genetic variants influencing drug metabolism by Cytochrome P450 (CYP) enzymes are crucial for personalized medicine. This study highlights ancestry-specific regulatory variants in CYP2D6, impacting drug response and necessitating updated pharmacogenetic testing.
Area of Science:
- Pharmacogenomics
- Molecular biology
- Genetics
Background:
- Cytochrome P450 (CYP) enzymes are critical for metabolizing the majority of pharmaceutical drugs.
- Limited understanding exists regarding regulatory genetic variants that influence CYP-mediated drug metabolism across diverse populations.
- Previous research has primarily focused on coding variants, neglecting the impact of regulatory variations.
Purpose of the Study:
- To comprehensively analyze regulatory variation across 54 Cytochrome P450 (CYP) genes using expression quantitative trait loci (eQTL) data.
- To identify specific CYP genes with significant regulatory variation and characterize their functional and population-specific implications.
- To assess the need for incorporating ancestry-specific regulatory variants into pharmacogenetic testing strategies.
Main Methods:
- Utilized the Genotype-Tissue Expression (GTEx) database to analyze eQTLs for 54 CYP genes.
- Performed in silico functional analysis to predict the impact of identified variants on transcription factor binding and chromatin accessibility.
- Investigated population stratification and linkage disequilibrium of key variants with known functional alleles.
Main Results:
- CYP2D6 exhibited the most extensive regulatory variation, with 249 identified variants, including two high-effect variants in strong linkage disequilibrium.
- In silico analysis indicated that one variant disrupts numerous transcription factor binding sites within an accessible chromatin region.
- These high-frequency variants (45% in East Asians vs. 2.5% in Europeans) are strongly linked to the reduced-function CYP2D6*10 allele.
Conclusions:
- Ancestry-specific regulatory variants significantly contribute to inter-individual variability in drug metabolism.
- The identified regulatory variants in CYP2D6 have substantial population-specific frequencies and functional implications.
- Pharmacogenetic testing strategies must be updated to include these ancestry-specific regulatory variants for improved drug efficacy and safety.
More Related Videos
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
20
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
20
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
01:27Principles of Pharmacogenetics: Types of Genetic Variants
22
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
22
01:27Pharmacogenetics of Drug Metabolism: Overview
23
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
23
01:29Pharmacogenomics: Identification of New Drug Targets
20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20